Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
Medtronic
McKinsey
Dow

Last Updated: August 13, 2022

Investigational Drug Information for Radotinib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Radotinib?

Radotinib is an investigational drug.

There have been 7 clinical trials for Radotinib. The most recent clinical trial was a Phase 3 trial, which was initiated on December 28th 2018.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and Leukemia. The leading clinical trial sponsors are Il-Yang Pharm. Co., Ltd., Asan Medical Center, and Ulsan University Hospital.

There are one hundred and fifteen US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Radotinib
TitleSponsorPhase
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseIl-Yang Pharm. Co., Ltd.Phase 2
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Il-Yang Pharm. Co., Ltd.Phase 3
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsIl-Yang Pharm. Co., Ltd.Phase 3

See all Radotinib clinical trials

Clinical Trial Summary for Radotinib

Top disease conditions for Radotinib
Top clinical trial sponsors for Radotinib

See all Radotinib clinical trials

US Patents for Radotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Radotinib See Plans and Pricing Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
Radotinib See Plans and Pricing .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) See Plans and Pricing
Radotinib See Plans and Pricing Heteroaryl compounds as IRAK inhibitors and uses thereof Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
Radotinib See Plans and Pricing Heteroaryl compounds as BTK inhibitors and uses thereof Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
Radotinib See Plans and Pricing Heteroaryl compounds as IRAK inhibitors and uses thereof Merck Patent GmbH (Darmstadt, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Radotinib

Drugname Country Document Number Estimated Expiration Related US Patent
Radotinib Argentina AR101414 2034-08-04 See Plans and Pricing
Radotinib Australia AU2015299431 2034-08-04 See Plans and Pricing
Radotinib Brazil BR112017000730 2034-08-04 See Plans and Pricing
Radotinib Canada CA2957154 2034-08-04 See Plans and Pricing
Radotinib China CN106660989 2034-08-04 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Moodys
Medtronic
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.